The clinical exploration of corticosteroid switch of abiraterone acetate in patients with metastatic castration-resistant prostate cancer
10.3760/cma.j.cn112330-20210408-00003
- VernacularTitle:激素转换在阿比特龙治疗转移性去势抵抗性前列腺癌中的临床探索
- Author:
Hao ZENG
1
;
Yuchao NI
;
Jinge ZHAO
Author Information
1. 四川大学华西医院泌尿外科，成都 610041
- Keywords:
Prostatic neoplasms;
Metastatic;
Castration-resistant;
Abiraterone acetate;
Dexamethasone;
Prednisone
- From:
Chinese Journal of Urology
2021;42(Z1):10-16
- CountryChina
- Language:Chinese
-
Abstract:
The terminal stage of prostate cancer is metastatic castration-resistant prostate cancer (mCRPC) with poor prognosis and high mortality. Abiraterone acetate (AA), as a new generation drug for endocrine therapy, has been demonstrated to prolonged overall survival signicantly in mCRPC patients. In addition, a corticosteroid drug must be administered during treatment to avoid side effects of abiraterone. It has been found that a corticosteroid switch from prednisone to dexamethasone could delay the development of resistance, significantly prolong the progression-free survival rate of patients, with well tolerance. But the specific mechanism and long-term clinical benefit still need further study. This emerging treatment paradigm provides new ideas for treatment options for patients with mCRPC, however, caution is still needed in clinical practice, and it is recommended to determine the treatment plan after considering all aspects of the patients.
